Sanofi-Aventis Q3 Results - Q3 Top Pharma Company Earnings Reports

View Sanofi-Aventis' Q3 Earnings Report


  • Good performances from Lovenox(R) (+13.7%) and Lantus(R) (+21.7%) across all three geographic regions, continuation of strong uptrend in the presence of Plavix(R) in the United States (+11.3%) and Japan (+50.3%)
  • Sales growth of 20.9% in emerging markets
  • Strong growth for the Pentacel(R) and Menactra(R) vaccines; substantial proportion of seasonal and A/H1N1 vaccines sales anticipated in the fourth quarter
  • OTC sales up 26.3%
  • Launch of Multaq(R) in the United States on target; positive opinion from the CHMP in Europe, and approval in Canada and Switzerland
  • Impact of competition from generics of Eloxatin(R) in the United States and Plavix(R) in some European countries more than offset by growth drivers

Check out Sanofi-Aventis' current earnings estimates from CNN Money

Sanofi-Aventis' Website:

Sanofi-Aventis Q3 Results - Q3 Top Pharma Company Earnings Reports

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.